专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

WO2012085650A1 SUBSTITUTED PYRIDINES AS SODIUM CHANNEL BLOCKERS 审中-公开
标题翻译：取代的吡啶作为钠通道阻断剂
公开(公告)号：WO2012085650A1
公开(公告)日：2012-06-28
申请号：PCT/IB2011/003137
申请日：2011-12-21
申请人： PURDUE PHARMA L.P. , NI, Chiyou , PARK, Minnie , SHAO, Bin , TAFESSE, Laykea , YAO, Jiangchao , YOUNGMAN, Mark , ZHOU, Xiaoming
发明人： NI, Chiyou , PARK, Minnie , SHAO, Bin , TAFESSE, Laykea , YAO, Jiangchao , YOUNGMAN, Mark , ZHOU, Xiaoming
IPC分类号： C07D213/75 , C07D401/02 , C07D401/12 , C07D401/14 , A61K31/44 , A61K31/4439 , A61P25/00
CPC分类号： C07D213/75 , C07D213/76 , C07D213/81 , C07D401/02 , C07D401/12 , C07D401/14 , C07D413/12
摘要： The invention relates to substituted pyridine compounds of Formula I: (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R 1a , R 1b , R 2a , R 2b , R 2c , A 1 , A 2 , and X are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.
摘要翻译：本发明涉及式I的取代的吡啶化合物：（I）及其药学上可接受的盐，前药和溶剂化物，其中R1a，R1b，R2a，R2b，R2c，A1，A2和X定义如规范。本发明还涉及式I化合物用于治疗对钠通道阻断作出反应的病症。本发明的化合物特别可用于治疗疼痛。

32. 发明申请

WO2012035421A3 PYRIDINE COMPOUNDS AND THE USES THEREOF 审中-公开
公开(公告)号：WO2012035421A3
公开(公告)日：2012-03-22
申请号：PCT/IB2011/002172
申请日：2011-09-16
申请人： PURDUE PHARMA L.P. , NI, Chiyou , SHAO, Bin , TAFESSE, Laykea , YAO, Jiangchao , YU, Jianming , ZHOU, Xiaoming
发明人： NI, Chiyou , SHAO, Bin , TAFESSE, Laykea , YAO, Jiangchao , YU, Jianming , ZHOU, Xiaoming
IPC分类号： C07D213/30 , C07D213/46 , C07D213/74 , C07D213/79 , C07D213/81 , C07D213/84 , C07D401/04 , C07D401/12 , C07D403/12 , C07D403/14 , A61K31/4418 , A61K31/4439 , A61K31/444 , A61P23/00
摘要： The invention relates to substituted pyridine compounds of Formula (I) and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein R 1a , A 1, A 2 , E, G, Z 1 , and Z 2 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.

33. 发明申请

WO2009087564A1 PROLINE ANALOGS AS LIGANDS FOR CANNABINOID RECEPTORS FOR THE TREATMENT OF PAIN 审中-公开
标题翻译：作为用于治疗疼痛的CANNABINOID受体的配体的简化模拟
公开(公告)号：WO2009087564A1
公开(公告)日：2009-07-16
申请号：PCT/IB2009/000023
申请日：2009-01-08
申请人： PURDUE PHARMA L.P. , SHAO, Bin , YAO, Jiangchao
发明人： SHAO, Bin , YAO, Jiangchao
IPC分类号： C07D207/48 , C07D409/12 , C07D409/14 , A61K31/381 , A61K31/401 , A61K31/4025 , A61P25/04
CPC分类号： C07D409/12 , C07D207/48 , C07D403/12 , C07D409/14
摘要： The present invention relates to Proline Analog Compounds that are ligands for cannabinoid receptors, compositions comprising a Proline Analog Compound and a pharmaceutically-acceptable carrier, methods of making such Proline Analog Compounds, and methods for treating or preventing a Condition comprising administering an effective amount of a Proline Analog Compound to an animal in need thereof.(Formula)
摘要翻译：本发明涉及作为大麻素受体的配体的脯氨酸类似物化合物，包含脯氨酸类似物化合物和药学上可接受的载体的组合物，制备此类脯氨酸类似物的方法，以及用于治疗或预防病症的方法，包括施用有效量的脯氨酸类似物化合物与需要的动物（式）

34. 发明申请

WO2005075459A1 SYNTHESIS OF CYANOIMINO-BENZOIMIDAZOLES 审中-公开
标题翻译： CYANOIMINO-BENZOIMIDAZOLES的合成
公开(公告)号：WO2005075459A1
公开(公告)日：2005-08-18
申请号：PCT/US2005/002824
申请日：2005-02-02
申请人： EURO-CELTIQUE S.A. , GOEHRING, R., Richard , WHITEHEAD, John , SHAO, Bin
发明人： GOEHRING, R., Richard , WHITEHEAD, John , SHAO, Bin
IPC分类号： C07D401/04
CPC分类号： C07D471/10 , C07D401/04
摘要： Disclosed in certain embodiments is a process for synthesizing a compound of formula (V) and salts thereof.
摘要翻译：在某些实施方案中公开了合成式（V）化合物及其盐的方法。

35. 发明申请

WO2013030665A1 PYRIMIDINES AS SODIUM CHANNEL BLOCKERS 审中-公开
标题翻译： PYRIMIDINES作为钠通道阻塞剂
公开(公告)号：WO2013030665A1
公开(公告)日：2013-03-07
申请号：PCT/IB2012/001871
申请日：2012-08-31
申请人： PURDUE PHARMA L.P. , NI, Chiyou , PARK, Minnie , SHAO, Bin , TAFESSE, Laykea , YAO, Jiangchao , YOUNGMAN, Mark
发明人： NI, Chiyou , PARK, Minnie , SHAO, Bin , TAFESSE, Laykea , YAO, Jiangchao , YOUNGMAN, Mark
IPC分类号： C07D233/90 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/12 , C07D405/14 , A61K31/4418 , A61P25/08
CPC分类号： C07D239/42 , A61K31/506 , C07D233/90 , C07D239/34 , C07D239/48 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/12 , C07D405/14 , C07D413/04
摘要： The present disclosure provides substituted pyrimidine compounds of Formula (I), and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein A 1 , X, A 2 , W 1 , W 2 , W 3 , E, Z, and R 4 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present disclosure are especially useful for treating pain.
摘要翻译：本公开提供式（I）的取代嘧啶化合物及其药学上可接受的盐，前药和溶剂合物，其中A1，X，A2，W1，W2，W3，E，Z和R4定义如规格。本公开还涉及式（I）化合物用于治疗对钠通道阻断有反应的病症。本公开的化合物特别可用于治疗疼痛。

36. 发明申请

WO2012158844A1 HETEROCYCLIC COMPOUNDS 审中-公开
标题翻译：杂环化合物
公开(公告)号：WO2012158844A1
公开(公告)日：2012-11-22
申请号：PCT/US2012/038215
申请日：2012-05-16
申请人： SHIONOGI & CO., LTD. , PURDUE PHARMA L.P. , KUROSE, Noriyuki , FUCHINO, Kouki , HATA, Kayoko , ISO, Yasuyoshi , YAMAGUCHI, Naoko , SHAO, Bin , TAFESSE, Laykea , ZHOU, Xiaoming , YU, Jianming
发明人： KUROSE, Noriyuki , FUCHINO, Kouki , HATA, Kayoko , ISO, Yasuyoshi , YAMAGUCHI, Naoko , SHAO, Bin , TAFESSE, Laykea , ZHOU, Xiaoming , YU, Jianming
IPC分类号： A61K31/165 , A61K31/44 , A61K31/497 , A01N43/40
CPC分类号： C07D413/14 , C07D271/06 , C07D271/10 , C07D401/04 , C07D401/14 , C07D405/14 , C07D413/04 , C07D413/12 , C07D417/14
摘要： The invention relates to compounds of Formula I: wherein Ar 1 , Ar 2 , Ar 3 , L 1 , L 2 , Y, Z and v are defined in the specification, and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative thereof.
摘要翻译：本发明涉及式I化合物：其中Ar1，Ar2，Ar3，L1，L2，Y，Z和v在本说明书中定义，及其药学上可接受的衍生物，包含有效量的式I化合物或药物可接受的衍生物，以及治疗或预防诸如疼痛，UI，溃疡，IBD和IBS的病症的方法，包括向有需要的动物施用有效量的式I化合物或其药学上可接受的衍生物。

37. 发明申请

WO2003022285A1 HETEROCYCLIC SUBSTITUTED 2- (4-PHENOXY) PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEURONAL DAMAGE AND NEURODEGENERATIVE CONDITIONS 审中-公开
标题翻译：杂环取代的2-（4-苯氧基）吡啶衍生物及相关化合物作为治疗神经损伤和神经营养因子的钠通道阻断剂
公开(公告)号：WO2003022285A1
公开(公告)日：2003-03-20
申请号：PCT/US2002/028299
申请日：2002-09-06
申请人： EURO-CELTIQUE S.A. , SHAO, Bin , GOEHRING, R., Richard
发明人： SHAO, Bin , GOEHRING, R., Richard
IPC分类号： A61K31/5377
CPC分类号： C07D213/64 , C07D213/81
摘要： This invention relates to aryl substituted pyridines of Formula (I) or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein: Ar is selected from the group consisting of Ar 1 , Ar 2 , Ar 3 and Ar 4 , wherein Ar 1 is R 1 is selected from the group consisting of an optionally substituted alkyl, amino, alkylthiol, C(O)R 10 , SO 2 R 10 , and OC(O)NH 2 ; R 2 is Y m -(CH 2 ) n -Z, wherein Y is O, S or NR 11 , wherein R 11 is hydrogen or alkyl, Z is a saturated heterocyclic ring optionally substituted at one or more carbon atoms, m is 0 or 1, and n is 0-6; or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Ar and R 1 -R 4 are set in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions such as amyothrophic lateral sclerosis (ALS), and for the treatment, prevention or amelioration of both acute or chronic pain, including diabetic neuropathy, as antitinnitus agents, as anticonvulsants, and as antimanic depressants, as local anesthetics, and as antiarrhythmics.
摘要翻译：本发明涉及式（I）的芳基取代的吡啶或其药学上可接受的盐，前药或溶剂合物，其中：Ar选自Ar1，Ar2，Ar3和Ar4，其中Ar1是R1选自由任选取代的烷基，氨基，烷基硫醇，C（O）R 10，SO 2 R 10和OC（O）NH 2组成; R2是Ym-（CH2）nZ，其中Y是O，S或NR11，其中R11是氢或烷基，Z是在一个或多个碳原子上任意取代的饱和杂环，m是0或1，n是0 -6; 或其药学上可接受的盐，前药或溶剂合物，其中Ar和R 1 -R 4置于说明书中。本发明还涉及式I化合物用于治疗全身和局部缺血后的神经元损伤，用于治疗或预防神经变性疾病如肌萎缩性侧索硬化（ALS）以及治疗，预防或改善急性或慢性疼痛，包括糖尿病性神经病，作为抗惊厥药，抗惊厥药，抗抑郁药，作为局部麻醉剂，以及作为抗心律失常药。

38. 发明申请

WO2009027820A2 SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF 审中-公开
标题翻译：替代 - 喹喔啉型哌啶化合物及其用途
公开(公告)号：WO2009027820A2
公开(公告)日：2009-03-05
申请号：PCT/IB2008/002291
申请日：2008-08-29
申请人： PURDUE PHARMA L.P. , SHIONOGI & CO., LTD. , GOEHRING, Richard, R. , MATSUMURA, Akira , SHAO, Bin , TAODA, Yoshiyuki , TSUNO, Naoki , WHITEHEAD, John, William, Frank , YAO, Jiangchao
发明人： GOEHRING, Richard, R. , MATSUMURA, Akira , SHAO, Bin , TAODA, Yoshiyuki , TSUNO, Naoki , WHITEHEAD, John, William, Frank , YAO, Jiangchao
IPC分类号： C07D401/04 , C07D401/14 , C07D451/04 , C07D451/14 , C07D471/14 , A61K31/498 , A61K31/4985 , A61P25/04
CPC分类号： C07D451/14 , A61K31/498 , C07D401/04 , C07D401/14 , C07D451/04 , C07D471/08 , C07D471/14 , C07D487/04 , C07D498/08 , C07D519/00
摘要： The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound.
摘要翻译：本发明涉及取代的喹喔啉型哌啶化合物，包含有效量的取代的喹喔啉型哌啶化合物的组合物和治疗或预防诸如疼痛的病症的方法，包括向有需要的动物施用有效量的取代的喹喔啉型哌啶化合物。

39. 发明申请

WO2008008398A3 OXIME COMPOUNDS AND THE USE THEREOF 审中-公开
公开(公告)号：WO2008008398A3
公开(公告)日：2008-01-17
申请号：PCT/US2007/015827
申请日：2007-07-12
申请人： SHIONOGI & CO., LTD. , EURO-CELTIQUE S.A , MATSUMURA, Akira , MIKAMIYAMA, Hidenori , TSUNO, Naoki , KYLE, Donald, J. , SHAO, Bin , YAO, Jiangchao
发明人： MATSUMURA, Akira , MIKAMIYAMA, Hidenori , TSUNO, Naoki , KYLE, Donald, J. , SHAO, Bin , YAO, Jiangchao
IPC分类号： A61K31/40 , C07D207/14
摘要： The invention relates to oxime compounds of Formula (I) and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein X is hydrogen, optionally substituted aryl, optionally substituted heteroaryl or the like; Y is CO, SO 2 , CR 3 R 4 or the like; Z is optionally substituted lower alkyl, optionally substituted aryl or the like; W is optionally substituted lower alkylene or optionally substituted lower alkenylene, R 3 and R 4 are each independently hydrogen, lower alkyl or the like; p is 0, 1, or 2 and q is O, 1 or 2. The invention is also directed to the use compounds of Formula I to treat, prevent or ameliorate a disorder responsive to the blockade of calcium channels, and particularly N-type calcium channels. Compounds of the present invention are especially useful for treating pain.

40. 发明申请

WO2007121659A1 POROUS METAL MATERIALS WITH ELLIPTIC TYPE PORES AND THEIR MANUFACTURING PROCESS 审中-公开
标题翻译：多孔金属材料及其制造工艺
公开(公告)号：WO2007121659A1
公开(公告)日：2007-11-01
申请号：PCT/CN2007/001107
申请日：2007-04-04
申请人： INCO ADVANCED TECHNOLOGY MATERIALS (DALIAN) CO., LTD , INCO ADVANCED TECHNOLOGY MATERIALS (SHENYANG) CO., LTD. , YU, Qing , ZHENG, Entao , WANG, Yumin , SHAO, Bin , HE, Fen , LI, Wei
发明人： YU, Qing , ZHENG, Entao , WANG, Yumin , SHAO, Bin , HE, Fen , LI, Wei
IPC分类号： C22C1/08 , C25D3/00
CPC分类号： C22C1/08 , B22F3/1103 , B22F2998/00 , B22F2999/00 , C25D5/56 , C25D7/00 , C25D13/00 , B22F3/1137
摘要： A porous metal with elliptic/quasi-elliptic pores, in which the aspect ratio, i.e., the ratio of longitudinal axial to transverse axial, is 1.5-10. The porous metal has excellent directional characteristics, significantly higher tensile strength and electric conductivity in longitudinal direction than that of the porous metal with equi-axial pores and with the same aerial metal density. A process for manufacturing the porous metal comprises the following steps: heating a polymeric foam sheet to the temperature at which the sheet becomes plastic; stretching the foam sheet; cooling the foam sheet to a temperature below the plastic point thereof; making the stretched sheet electric conductive; and electroplating the foam sheet with a desired metal.
摘要翻译：具有椭圆/准椭圆形孔的多孔金属，其中纵横比即纵向轴向与横向轴向的比率为1.5-10。多孔金属具有优异的定向特性，纵向方向上的拉伸强度和电导率显着高于具有等轴孔隙和相同空间金属密度的多孔金属。制造多孔金属的方法包括以下步骤：将聚合物泡沫片材加热到片材变成塑料的温度; 拉伸泡沫片材; 将泡沫片材冷却至其塑性点以下的温度; 使拉伸片材导电; 并用所需的金属电镀泡沫片材。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式